1. Generics Bulletin
  2. >>Products

Golimumab Results Lead Off A Raft Of Updates For Alvotech

Firm Also Provides Updates On FDA Inspection And Adalimumab, Ustekinumab Expectations

 
• By Dave Wallace

Alvotech has provided a slew of updates on its biosimilars business, including clinical trial results for its Simponi rival as well as the latest on a key US FDA inspection of its manufacturing facility and fresh details around its launches of Humira and Stelara rivals in the US and around the world.

Updates message on computer screen
Alvotech has provided multiple updates on its biosimilars • Source: Shutterstock

Alvotech’s biosimilars business is showing no signs of slowing down, with the latest quarterly business update for the Icelandic company bringing multiple fresh details on various products in its pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.